Hemophilia Disease Forecast and Market Analysis to 2035: Forecasts, Treatment, Epidemiology, Marketed Drugs & Pipeline

Dublin, May 30, 2017 -- Research and Markets has announced the addition of the "Hemophilia Disease Forecast and Market Analysis to 2035" report to their offering.

Hemophilia is a relatively rare hereditary genetic disorder characterized by an inability to produce a clot capable of stopping bleeding. Mainly men are affected by hemophilia A (factor VIII-deficient) and hemophilia B (factor IX-deficient), as is the case with most recessive, X-chromosomal disorders. In congenital hemophilia, the impaired production or functioning of one of the factors involved in the coagulation cascade is responsible for compromised blood coagulation, leading to uncontrolled and prolonged bleeding. The current standard of treatment for these patients is the replacement of the missing factor via clotting factor concentrate products. However, some patients develop antibodies against these therapies, called inhibitors, making treatment much more difficult.

Patients without hemophilia who develop inhibitors against clotting factor VIII or factor IX are diagnosed as having acquired hemophilia A or B, respectively. Although acquired hemophilia patients and congenital hemophilia patients with inhibitors share some similar traits and treatment options, acquired hemophilia affects men and women similarly, and has a distinct bleeding pattern.

Another disease associated with blood coagulation dysfunction is von Willebrand disease, which is caused by a deficiency in von Willebrand factor. Although von Willebrand disease is more common than hemophilia, it is relatively less severe, with most patients exhibiting mild disease that does not require regular treatment unless bleeding episodes caused by trauma or invasive procedures are uncontrollable.

Key Topics Covered:

1. FORECAST: HEMOPHILIA
Executive Summary
Market Overview and Trends
Methodology and Market Definition
Advate
Adynovate
Alprolix
BAX 817
BAY 94-9027
BeneFIX
CSL627
Eloctate
FEIBA
Idelvion
Ixinity
Kogenate/Helixate and Kovaltry
N8-GP
N9-GP
NovoEight
NovoSeven
Nuwiq
Rixubis
Vonvendi
Xyntha/ReFacto
Primary Research Methodology

2. TREATMENT: HEMOPHILIA
Executive Summary
Primary Research Methodology
Disease Definition and Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends

3. EPIDEMIOLOGY: HEMOPHILIA
Executive Summary
Disease Background
Sources and Methodology
Forecast: Hemophilia
Forecast: Von Willebrand Disease
Epidemiologist Insight
Strengths and Limitations
Appendix

4. MARKETED DRUGS: HEMOPHILIA
Executive Summary
Product Overview
Products Approved for Acquired Hemophilia
Products Approved for Von Willebrand Disease
Appendix
Product profile: Advate
Product profile: Adynovate
Product profile: Alprolix
Product profile: BeneFIX
Product profile: Eloctate
Product profile: FEIBA
Product profile: Idelvion
Product profile: Ixinity
Product profile: Kogenate FS
Product profile: NovoEight
Product profile: NovoSeven
Product profile: Rixubis
Product profile: Xyntha

5. PIPELINE: HEMOPHILIA
Executive Summary
Clinical Pipeline Overview
Target Product Profile
Clinical Trial Design
Product profile (late stage): BAX 817
Product profile (late stage): BAY 94-9027
Product profile (late stage): CSL627
Product profile (late stage): CSL689
Product profile (late stage): Kovaltry
Product profile (late stage): LR769
Product profile (late stage): N8-GP
Product profile (late stage): N9-GP
Product profile (late stage): emicizumab

6. APPENDIX
Appendix: Pipeline: Hemophilia

For more information about this report visit http://www.researchandmarkets.com/research/5lb7vb/hemophilia

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Hematological Drugs